The effect of Donepezil on memory impairment after Covid-19

Phase 3

• Conditions: Memory impairment due to Post acute COVID-19 syndrome (LONG-Covid Syndrome).; SARS-associated coronavirus as the cause of diseases classified elsewhere; B97.21

• Registration Number: IRCT20210816052203N1
• Lead Sponsor: Artesh University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients with the age between 20- 50 years old
Memory impairment after recovery from Covid-19
Volunteer to participate in the study

Exclusion Criteria

History of previous cognitive problems
History of CVA, head trauma or Cerebral hemorrhage
History of underlying physical illnesses affecting cognitive function such as cancer, thyroid disorders, physical disorders with features of cognitive impairment such as Alzheimer's or any type of degenerative neurological disorder such as Parkinson's
History of underlying mental illnesses such as major depression, anxiety disorders and psychotic disorders
Use of drugs that affect cognitive function such as antidepressants, benzodiazepines, and anticonvulsants such as phenobarbital
Drug, stimulant and alcohol using

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Score of Wechsler Memory Scale Test. Timepoint: Measurement of memory indices at the beginning of the study (before intervention), one month later, three months later and six months after the intervention. Method of measurement: The Wechsler Memory Scale.